MET 4
Alternative Names: MET-4Latest Information Update: 21 Sep 2023
At a glance
- Originator NuBiyota
- Class Antineoplastics; Bacteria
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Solid tumours
- Phase II Squamous cell cancer
Most Recent Events
- 12 May 2023 Phase-II clinical trials in Squamous cell cancer (Late-stage disease, Combination therapy) (PO) (NCT05743777)
- 12 May 2023 Nubiyota terminates a phase II trial in Squamous cell cancer (Late stage disease, Combination therapy) due to financial reasons (NCT05743777)